Operating Income (Loss) of Achilles Therapeutics plc from 31 Dec 2019 to 30 Jun 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Achilles Therapeutics plc quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2019 to 30 Jun 2024.
Achilles Therapeutics plc Operating Income (Loss) for the quarter ending 30 Jun 2024 was $17,799,000, a 1.6% increase year-over-year.
Achilles Therapeutics plc annual Operating Income (Loss) for 2023 was $75,255,000, a 4% increase from 2022.
Achilles Therapeutics plc annual Operating Income (Loss) for 2022 was $78,383,000, a 22% decline from 2021.
Achilles Therapeutics plc annual Operating Income (Loss) for 2021 was $64,195,000, a 90% decline from 2020.
Source SEC data: View on sec.gov

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Change (%)

Operating Income (Loss), Annual (USD)

Operating Income (Loss), YoY Annual Change (%)

Achilles Therapeutics plc Quarterly Operating Income (Loss) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2024	$17,799,000	+$293,000	+1.6%	01 Apr 2024	30 Jun 2024	6-K	14 Aug 2024	2024	Q2
Q2 2023	$18,092,000	+$2,454,000	+12%	01 Apr 2023	30 Jun 2023	6-K	14 Aug 2024	2024	Q2
Q2 2022	$20,546,000			01 Apr 2022	30 Jun 2022	6-K	04 Aug 2023

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2023	$75,255,000	+$3,128,000	+4%	01 Jan 2023	31 Dec 2023	20-F	04 Apr 2024	2023	FY
2022	$78,383,000	-$14,188,000	-22%	01 Jan 2022	31 Dec 2022	20-F	04 Apr 2024	2023	FY
2021	$64,195,000	-$30,468,000	-90%	01 Jan 2021	31 Dec 2021	20-F	04 Apr 2024	2023	FY
2020	$33,727,000	-$19,952,000	-145%	01 Jan 2020	31 Dec 2020	20-F	07 Mar 2023	2022	FY
2019	$13,775,000			01 Jan 2019	31 Dec 2019	20-F	01 Mar 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.